Mohammad Yunus, MD
Internal Medicine · Bonifay, FLNPI 1730165259
Payments from drug & device makers
Across 370 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Grifols USA, LLC$877
- Lilly USA, LLC$540
- AstraZeneca$418
- Merck$342
- Novartis$315
- plus $2K from 29 others
What the payments were for
- Food & beverage$6,351100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 94 | $1,430 |
| Grifols USA, LLC | 56 | $877 |
| Lilly USA, LLC | 33 | $540 |
| AstraZeneca | 28 | $418 |
| Merck | 18 | $342 |
| Novartis | 20 | $315 |
| Pfizer | 12 | $244 |
| GSK | 13 | $237 |
| Amgen | 12 | $210 |
| Novo Nordisk | 11 | $183 |
| Otsuka America Pharmaceutical, Inc. | 9 | $173 |
| Johnson & Johnson | 6 | $154 |
| Verona Pharma, Inc. | 6 | $154 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $150 |
| Bayer | 5 | $113 |
| CSL Behring | 5 | $99 |
| Insmed, Inc. | 5 | $98 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $74 |
| Vivus LLC | 3 | $69 |
| Vanda Pharmaceuticals Inc. | 3 | $68 |
| Avanir Pharmaceuticals, Inc. | 3 | $45 |
| Supernus Pharmaceuticals, Inc. | 2 | $36 |
| Biogen | 2 | $35 |
| Eisai Inc. | 2 | $34 |
| Vifor Pharma, Inc. | 1 | $30 |
| Dexcom, Inc. | 1 | $30 |
| Lundbeck LLC | 1 | $28 |
| GRT US Holding, Inc. | 1 | $26 |
| Sanofi | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
How this compares
$6,351 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Avonex (4 Pack)Interferon Beta-1a | 11 | $95,543 |
| EliquisApixaban | 288 | $83,074 |
| TrulicityDulaglutide | 60 | $41,353 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $36,846 |
| EntrestoSacubitril/Valsartan | 76 | $31,451 |
| PrezistaDarunavir | 11 | $24,953 |
| OzempicSemaglutide | 17 | $17,176 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 165 | $16,791 |
| MyrbetriqMirabegron | 67 | $16,702 |
| FarxigaDapagliflozin Propanediol | 34 | $15,938 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 739 | $15,614 |
| JanuviaSitagliptin Phosphate | 50 | $15,411 |
| XareltoRivaroxaban | 49 | $14,893 |
| SantylCollagenase Clostridium Hist. | 46 | $14,731 |
| LinzessLinaclotide | 21 | $11,693 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenAvonex (4 Pack) | $35 | $95,54311 claims |
| PfizerEliquis | $244 | $83,074288 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $237 | $48,30279 claims |
| Lilly USA, LLCTrulicity | $540 | $41,35360 claims |
| NovartisEntresto | $315 | $31,45176 claims |
| AbbVieLinzess, Restasis, Qulipta | $1,430 | $30,42953 claims |
| AstraZenecaFarxiga, Lokelma, Symbicort | $418 | $25,12880 claims |
| Johnson & JohnsonXarelto, Procrit | $154 | $19,75866 claims |
| Novo NordiskOzempic | $183 | $17,17617 claims |
| MerckJanuvia | $342 | $15,41150 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $150 | $6,11025 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $45 | $4,74413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Bonifay
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.